{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "1317694",
  "DateCompleted": {
    "Year": "1992",
    "Month": "07",
    "Day": "02"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "06",
    "Day": "19"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0003-4819",
      "JournalIssue": {
        "Volume": "117",
        "Issue": "1",
        "PubDate": {
          "Year": "1992",
          "Month": "Jul",
          "Day": "01"
        }
      },
      "Title": "Annals of internal medicine",
      "ISOAbbreviation": "Ann Intern Med"
    },
    "ArticleTitle": "Effects of naproxen on experimental rhinovirus colds. A randomized, double-blind, controlled trial.",
    "Pagination": {
      "StartPage": "37",
      "EndPage": "41",
      "MedlinePgn": "37-41"
    },
    "Abstract": {
      "AbstractText": [
        "To determine whether naproxen, a propionic acid inhibitor of cyclooxygenase, alters the course of experimental rhinovirus colds.",
        "A randomized, double-blind, controlled trial.",
        "Rhinovirus challenge model in volunteers cloistered in individual hotel rooms.",
        "Eighty-seven healthy young adults with serum neutralizing antibody titers of less than or equal to 1:2 to the challenge virus; 79 were evaluable.",
        "Thirty-nine participants received naproxen (loading dose, 400 mg or 500 mg followed by 200 mg or 500 mg three times daily for 5 days). Forty participants received placebo. Treatment was started 6 hours after viral challenge.",
        "Daily measurement of viral titers, symptoms, nasal mucus production, and nasal tissue use; incidence of infection and illness; and measurement of homotypic serum neutralizing antibody responses.",
        "Viral titers and serum homotypic antibody responses were similar in the naproxen and placebo groups. Significant reductions in headache, malaise, myalgia, and cough occurred in the naproxen group. A 29% reduction was noted in the total (5-day) symptom score in the naproxen group (95% CI, 16% to 42%).",
        "Naproxen treatment did not alter virus shedding or serum neutralizing antibody responses in participants with experimental rhinovirus colds, but it had a beneficial effect on the symptoms of headache, malaise, myalgia, and cough. Prostaglandins may be among the inflammatory mediators that play a role in the pathogenesis of rhinovirus colds."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Virginia Health Sciences Center, Charlottesville."
          }
        ],
        "LastName": "Sperber",
        "ForeName": "S J",
        "Initials": "SJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Hendley",
        "ForeName": "J O",
        "Initials": "JO"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Hayden",
        "ForeName": "F G",
        "Initials": "FG"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Riker",
        "ForeName": "D K",
        "Initials": "DK"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Sorrentino",
        "ForeName": "J V",
        "Initials": "JV"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gwaltney",
        "ForeName": "J M",
        "Initials": "JM",
        "Suffix": "Jr"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Journal Article",
      "Randomized Controlled Trial",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Ann Intern Med",
    "NlmUniqueID": "0372351",
    "ISSNLinking": "0003-4819"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Viral"
    },
    {
      "RegistryNumber": "57Y76R9ATQ",
      "NameOfSubstance": "Naproxen"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Antibodies, Viral"
    },
    {
      "QualifierName": [
        "drug therapy",
        "immunology",
        "microbiology"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Naproxen"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Neutralization Tests"
    },
    {
      "QualifierName": [
        "drug effects",
        "immunology"
      ],
      "DescriptorName": "Rhinovirus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Severity of Illness Index"
    }
  ]
}